Pioglitazone may lower plaque inflammation in type 2 diabetes

10/12/2011 | MedPage Today (free registration)

Patients with carotid atherosclerosis and type 2 diabetes or impaired glucose tolerance who took 15 to 30 milligrams of pioglitazone for four months attained similar fasting plasma glucose levels as those who took glimepiride, but showed significant improvements in atherosclerotic plaque inflammation compared with the glimepiride-treated group, according to a study in JACC: Cardiovascular Imaging. Researchers found that patients who took pioglitazone had increased levels of high-density lipoprotein, which may have helped to suppress atherosclerotic plaque.

View Full Article in:

MedPage Today (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice-President of Technology and Regulatory Affairs
AdvaMed
Washington DC, DC
Sr Product Manager Global Marketing (US/DA/00/0085/SL) - 14000009V3
Abbott
Chicago, IL
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Vice President, Information Technology
HealthPartners
MN